| 本文已被：浏览 52次 下载 22次 |
码上扫一扫！ |
| 钇-90选择性内放射治疗在不可切除肝细胞癌转化治疗中的研究进展 |
| 赵曼1,2,倪倩雯1,2,朴贤杰1,2,吴晓勤1,2,周瑞1,2,张恺廷1,2,汪珍光2,邹明皓2,周文炫2,刘福晨2,刘辉1,2* |
|
|
(1. 上海理工大学健康科学与工程学院, 上海 200093;
2. 海军军医大学(第二军医大学)第三附属医院肝外三科, 上海 200438
*通信作者) |
|
| 摘要: |
| 钇-90（90Y）选择性内放射治疗（SIRT）是一种利用放射性核素90Y对肝细胞癌进行治疗的新型方法。90Y半衰期较长，可利用其高能β射线对肿瘤细胞进行定向杀伤，具有较高的生物学效应和较好的局部控制能力。近年来，随着相关基础研究和临床研究的不断深入，90Y-SIRT在不可切除肝细胞癌转化治疗中的应用取得了显著进展。然而，90Y-SIRT在临床应用中仍面临一些挑战，包括如何提高转化治疗效果、优化治疗方案等。本文对90Y-SIRT在不可切除肝细胞癌转化治疗中的研究进展进行综述。 |
| 关键词: 钇-90 选择性内放射治疗 肝肿瘤 不可切除肝细胞癌 转化治疗 |
| DOI：10.16781/j.CN31-2187/R.20240273 |
| 投稿时间：2024-04-28修订日期：2024-12-09 |
| 基金项目:国家自然科学基金（82270634）. |
|
| Yttrium-90 selective internal radiotherapy in conversion treatment of unresectable hepatocellular carcinoma: research progress |
| ZHAO Man1,2,NI Qianwen1,2,PIAO Xianjie1,2,WU Xiaoqin1,2,ZHOU Rui1,2,ZHANG Kaiting1,2,WANG Zhenguang2,ZOU Minghao2,ZHOU Wenxuan2,LIU Fuchen2,LIU Hui1,2* |
(1. School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200093, China;
2. Department of Hepatic Surgery (Ⅲ), The Third Affiliated Hospital of Naval Medical University (Second Military Medical University), Shanghai 200438, China
*Corresponding author) |
| Abstract: |
| Yttrium-90 (90Y) selective internal radiation therapy (SIRT) is an emerging modality for the treatment of hepatocellular carcinoma (HCC), leveraging the nuclide 90Y to deliver targeted radiation therapy. 90Y has a long half-life and can be used to selectively ablate tumor cells by high-energy beta rays. It has high biological effectiveness and robust local control capabilities. In recent years, with the continuous advancement of basic and clinical research, the application of 90Y-SIRT in the conversion treatment of unresectable HCC (uHCC) has made significant progress. However, challenges remain in the clinical application of 90Y-SIRT, including how to improve the efficacy of conversion therapy and how to optimize therapy regimens. This review aims to summarize the research progress of 90Y-SIRT in the conversion therapy of uHCC. |
| Key words: yttrium-90 selective internal radiotherapy liver neoplasms unresectable hepatocellular carcinoma conversion therapy |
